CAMBRIDGE, Mass.– Deep Genomics, an AI-driven biotechnology company pioneering the development of genomic medicines through its foundation model platform, announced the appointment of industry veterans Thong Q. Le and Paul Sekhri to its Board of Directors.
“We feel incredibly lucky to have the talents of Thong and Paul join our Board of Directors,” said Brian O’Callaghan, Chief Executive Officer of Deep Genomics. “Their collective decades of experience shaping the life sciences and biotechnology industry will be invaluable as we continue toward our mission of delivering AI-powered genetic medicines to patients.”
Thong Q. Le brings more than two decades of life sciences investment experience, with a proven record of advancing transformative healthcare innovations. He currently serves as investment director and managing partner of the Strategic Investment Fund (SIF) for the Bill & Melinda Gates Foundation and is chairman of Accelerator Life Science Partners (ALSP), a venture capital firm that develops next-generation biotechnology companies. Le has held leadership roles as director, founding president, and CEO of more than a dozen ALSP portfolio companies, including Petra Pharma, Rodeo Therapeutics, and Lodo Therapeutics, and serves on multiple biotech and nonprofit boards.
“In my time working with this industry, I’ve seen firsthand how the right combination of science, technology, and leadership can transform what’s possible in drug discovery,” said Le. “Deep Genomics has all of those ingredients, and I’m thrilled to have this opportunity to help guide its continued growth.”
Paul Sekhri currently serves as Chair, President, and CEO of vTv Therapeutics Inc., Chair of the Board of Resolution Therapeutics, and Executive Chair of Violet Therapeutics Inc. With more than 35 years of experience in business development and strategy, Sekhri has held senior leadership positions at major pharmaceutical and biotech companies including Sanofi, Teva Pharmaceuticals, TPG Biotech, Cerimon Pharmaceuticals, Ariad Pharmaceuticals, and Novartis. He also serves on the boards of Veeva Systems, AdhereTech, and Kayothera, is Chair of Young Concert Artists (YCA), and sits on the Advisory Council of the New York Philharmonic.
“I am excited to be joining the Deep Genomics Board at such a pivotal time in therapeutics, and I remain inspired by their ability to advance a new generation of medicines with the power of AI,” said Sekhri. “I look forward to contributing to such important TechBio advancements alongside this talented team.”
